Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
A 134.56 -0.48% -0.65
ABBV closed down 1.15 percent on Wednesday, January 19, 2022, on approximately normal volume.
Earnings due: Feb 1
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Flat
Historical ABBV trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish -0.50%
Pocket Pivot Bullish Swing Setup -1.64%
Bullish Engulfing Bullish -0.98%
Crossed Above 20 DMA Bullish -0.98%
Pocket Pivot Bullish Swing Setup -0.98%
Three Weeks Tight Range Contraction -0.98%
Outside Day Range Expansion -0.98%
Fell Below 20 DMA Bearish 0.76%
Gapped Down Weakness 0.76%
New 52 Week Closing High Bullish -2.00%
Older End-of-Day Signals for ABBV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 3 hours ago
Down 1% about 3 hours ago
Fell Below 20 DMA about 3 hours ago
10 DMA Support 1 day ago
20 DMA Support 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AbbVie Inc. Description

AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Acid Autoimmune Disease Pharmaceutical Products Chemical Compounds Organic Compounds Prostate Cancer Distribution Center Thyroid Cardiology Respiratory Diseases Cholesterol Anesthesia Chloroarenes Lipoprotein Testosterone Gabaa Receptor Positive Allosteric Modulators Triglyceride Hyperparathyroidism Low Density Lipoprotein Advanced Prostate Cancer Carbidopa Niacin Secondary Hyperparathyroidism Anesthesia Product Celiac Celiac Disease Exocrine Pancreatic Insufficiency Hypothyroidism Research Based Biopharmaceutical Testosterone Replacement Therapy

Is ABBV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 138.15
52 Week Low 101.8117
Average Volume 5,936,005
200-Day Moving Average 116.38
50-Day Moving Average 126.18
20-Day Moving Average 134.96
10-Day Moving Average 135.80
Average True Range 2.36
ADX 44.15
+DI 28.90
-DI 16.18
Chandelier Exit (Long, 3 ATRs) 131.06
Chandelier Exit (Short, 3 ATRs) 135.32
Upper Bollinger Bands 138.36
Lower Bollinger Band 131.55
Percent B (%b) 0.54
BandWidth 5.04
MACD Line 2.73
MACD Signal Line 3.34
MACD Histogram -0.6106
Fundamentals Value
Market Cap 238.71 Billion
Num Shares 1.77 Billion
EPS 4.57
Price-to-Earnings (P/E) Ratio 29.57
Price-to-Sales 4.13
Price-to-Book 12.13
PEG Ratio 1.28
Dividend 5.20
Dividend Yield 3.85%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 139.20
Resistance 3 (R3) 139.52 138.51 138.54
Resistance 2 (R2) 138.51 137.49 138.35 138.31
Resistance 1 (R1) 136.86 136.87 136.36 136.54 138.09
Pivot Point 135.85 135.85 135.60 135.69 135.85
Support 1 (S1) 134.20 134.83 133.70 133.88 132.33
Support 2 (S2) 133.19 134.21 133.03 132.11
Support 3 (S3) 131.54 133.19 131.89
Support 4 (S4) 131.22